Opus Genetics, Inc. (IRD)
NASDAQ: IRD · Real-Time Price · USD
4.940
+0.050 (1.02%)
Mar 9, 2026, 1:50 PM EDT - Market open
Opus Genetics Revenue
Opus Genetics had revenue of $3.08M in the quarter ending September 30, 2025, a decrease of -20.38%. This brings the company's revenue in the last twelve months to $14.63M, up 74.60% year-over-year. In the year 2024, Opus Genetics had annual revenue of $10.99M, down -42.30%.
Revenue (ttm)
$14.63M
Revenue Growth
+74.60%
P/S Ratio
23.05
Revenue / Employee
$812,944
Employees
18
Market Cap
340.68M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| X4 Pharmaceuticals | 33.98M |
| Foghorn Therapeutics | 24.52M |
| Neurogene | 925.00K |
| Avalo Therapeutics | 192.00K |
| Adlai Nortye | -1.35M |
IRD News
- 6 days ago - Opus Genetics to Present at Upcoming Investor Conferences in March 2026 - GlobeNewsWire
- 10 days ago - Opus Genetics Announces Initial Clinical Data from Phase 1/2 OPGx-BEST1 Gene Therapy Study at the Macula Society Annual Meeting - GlobeNewsWire
- 12 days ago - Opus Genetics Announces FDA Acceptance of Supplemental New Drug Application for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia - GlobeNewsWire
- 14 days ago - Opus Genetics: Asymmetric Upside With LCA5 And BEST1 - Seeking Alpha
- 24 days ago - Opus Genetics Announces $25 Million Private Placement - GlobeNewsWire
- 5 weeks ago - Opus Genetics to Participate in Upcoming Medical and Industry Conferences in February 2026 - GlobeNewsWire
- 5 weeks ago - Opus Genetics Launches Gene Therapy Clinical Trial for MERTK-related Retinitis Pigmentosa - GlobeNewsWire
- 7 weeks ago - Opus Genetics, Inc. (IRD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha